Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ATYR PHARMA, INC. reported revenue of $0M, down 19.1% year over year. Operating margin was -40856.3% and net margin -39009.5%, on a free-cash-flow margin of -32664.7% with capital expenditure at 40.5% of revenue. Every figure is computed directly from ATYR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -40856.3% | -39009.5% |
| FY2024 | $0M | -28899.6% | -27243.8% |
| FY2023 | $0M | -15557.8% | -14274.5% |
| FY2022 | $10M | -446.8% | -436.5% |
| FY2021 | $0M | n/a | n/a |
How does ATYR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.